Treatment of Breakpoint Cluster Region-Abelson (BCR-ABL) Negative ALL in Adults

After consolidation therapy adult patients (≥18 yr) with Ph-negative ALL will be treated with continuation chemotherapy or allogeneic hematopoietic stem cell transplantation (alloHSCT) according to both measurable residual disease (MRD) and results of genetic study performed at baseline.

Trial Details

NCT ID
NCT04179929
Phase
NA
Sponsor
PETHEMA Foundation
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Pediatric-type of chemotherapy
  • allogeneic HSCT
Locations (sample)
  • Badalona, Barcelona, Spain|41.45004,2.24741
  • Barcelona, Spain|41.38879,2.15899
  • A Coruña, Spain|43.37135,-8.396
  • Albacete, Spain|38.99424,-1.85643
  • Alicante, Spain|38.34517,-0.48149

Key Eligibility Criteria

  • Patients 18-60 yr with de novo Ph-neg ALL
  • Eastern Cooperative Oncology Group (ECOG) 0-2 (or \>2 if due to ALL)
  • Informed consent

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →